Skip to content

Trial · Interventional

TerminatedPhase 4Registry data

Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease

Short name DEPOPA

NCTNCT00806468 (opens ClinicalTrials.gov in a new tab)Other idDEPOPA-2008
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Terminated
Phase
Phase 4
Enrollment
1 participants (actual)
Sponsor
Johannes Gutenberg University Mainz · Other
Design
Randomized · Double masking
Countries
1 country

Germany

Start
Feb 2009
Primary completion
Dec 2010 (estimated)
Completion
Feb 2011 (estimated)
First posted
10 Dec 2008 (estimated)
Last update posted
20 Dec 2010 (estimated)
Conditions
Parkinson Disease

Timeline

1 trial · 1 stopped early

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2009201020112012
  1. Ph 4

    DEPOPA

    NCT00806468

    Feb 2009 to est. Feb 2011

    Terminated

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This study will be conducted to study the effect of Desmopressin on the nocturnal micturition frequency in patients with idiopathic Parkinson syndrome.

Interventions

  • DesmotabsDrug

Arms1

  • Experimental

    Desmopressin

    Desmopressin 0,2 mg once daily and Desmopressin 0,2 mg bid for one week each.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. average nocturnal micturition frequency within the 2 weeks treatment phase each

    Time frame · 6 weeks

Secondary outcomes(1)

  1. safety and efficacy on nocturnal micturition frequency of Desmopressin in patients with Parkinson syndrome

    Time frame · 8 weeks

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
Male
Age
from 18 Years up to 85 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Male patients with idiopathic Parkinson Syndrome * 18 to 85 years * Nocturnal Pollakisuria \> 2 mictions /night (documented in Screening phase ) * Na+ i.S \> 135 mmol/l * Patient is able to understand all aspects and individual consequences of the clinical trial * An informed consent signed and dated by the patient is available prior to any study specific treatment * The study is consistent with the patients´ request for an appropriate treatment Exclusion Criteria: * Intake of the following concomitant medication: Carbamazepin, Oxcarbazepine, diuretics (Furosemide, Torasemide), non steroidal antiphlogistics, Loperamide, antidiuretic hormone analoga (besides study medication), drugs for treatment of bladder disfunction, in particular anticholinergics * Central Diabetes insipidus * Known heart insufficiency (NYHA Stad. III und IV) * clinical relevant kidney insufficiency * Habitual and psychogenic Polydipsia * Hypersensitivity or allergy against the trial medication or any other ingredient of the trial medication * Participation in another clinical trial during or within 6 months prior to this clinical trial * Medical or psychological condition, which might endanger the proper conduction of the clinical trial * Known drug or alcohol abuse

PepBank is a research reference. Talk to a doctor before you use any peptide.